Phase 3
Completed N=62
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
Chemotherapy-Induced Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Source: ClinicalTrials.gov NCT00553059 ↗
Enrolled (actual)
62
Serious AEs
3.4%
Results posted
Oct 2020
Primary outcomePrimary: Number of Participants With Total Protection in the Acute, Delayed and Overall Periods — 22; 14; 11; 5 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving chemotherapy. The safety of the drug combinations will also be studied.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Total Protection in the Acute, Delayed and Overall Periods |
22; 14; 11; 5; 11; 5 | — |
| SECONDARY Number of Participants With Complete Protection for the Acute, Delayed, and Overall Periods |
22; 18; 14; 10; 14; 9 | — |
| SECONDARY Number of Participants With Complete Response for the Acute, Delayed, and Overall Periods |
22; 19; 14; 13; 15; 12 | — |
| SECONDARY Number of Participants With Vomiting for the Acute, Delayed and Overall Periods |
6; 3; 10; 9; 19; 19 | — |
| SECONDARY Number of Participants With Nausea for the Acute, Delayed and Overall Periods |
8; 15; 19; 23; 11; 5 | — |
| SECONDARY Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods |
4; 2; 7; 8; 15; 10 | — |
| SECONDARY Number of Participants Received Rescue Medication in the Acute, Delayed and Overall Periods |
3; 5; 11; 15; 10; 12 | — |
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically documented solid tumor
- Receiving moderately emetogenic chemotherapy for the first time: Patients may be chemotherapy naive, or patients may have previously received a mildly emetogenic agent (such as a taxane) if no nausea/vomiting was experienced with that chemotherapy
- Scheduled to receive cyclophosphamide /= 40 mg/m^2 IV given as single doses on Day 1. Patients on combination regimens with these agents are eligible
- Age >/= 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Adequate organ reserve as follows: 1) Hematologic - white blood cell count (WBC) >/= 3000/microL, AGC >/= 1500/microL, platelet >/= 100,000/microL; 2) Renal - Creatinine </= 1.5 times upper limit of normal; 3) Hepatic - Bilirubin and transaminases </= 2.5 times upper limit of normal
- The effects of the three-drug regimen on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Negative qualitative B-human chorionic gonadotropin (HCG) (pregnancy test)
- Signed informed consent
Exclusion Criteria
- Scheduled to receive highly emetogenic chemotherapy (Hesketh Level 5 - such as cisplatin, streptozotocin, dacarbazine, carmustine, hexamethylmelamine, mechlorethamine, procarbazine) during the study period
- Scheduled to receive moderately emetogenic chemotherapy (Hesketh Level 3-4) after Day 1 of the study period
- Experienced nausea and/or vomiting with prior administration of chemotherapy
- Prior moderately or highly emetogenic chemotherapy: Patients may have previously received a mildly emetogenic agent (such as a taxane) if no nausea/vomiting was experienced with that chemotherapy
- Scheduled to receive cranial, abdominal, or pelvic radiation therapy during the study period
- Treatment with any investigational agent within 30 days of randomization
- Scheduled to receive treatment during the study period with other potential or known antiemetic agents. Chronically used benzodiazepines may be continued as a single nightly dose for sleep.
- Scheduled to receive corticosteroid treatment other than the study drug dose during the study period
- Uncontrolled primary or metastatic CNS tumor (including those with uncontrolled seizures)
- Other physical causes for nausea or vomiting (such as bowel obstruction) not related to chemotherapy administration
- Recent history of unexplained nausea or vomiting or history of frequent nausea or vomiting
- Active bacterial or fungal infection for which administration of a corticosteroid would be contraindicated
- Hypersensitivity to any of the study agents
- Sensitivity to sesame oil
- Planned simultaneous administration of any other investigational agents
- Pregnant or nursing women
- Previous poor tolerance of cannabinoids
- Habitual cannabinoid use or unwillingness to avoid the use of marijuana during the study period
- Previous use of dronabinol or nabilone
Data sourced from ClinicalTrials.gov (NCT00553059). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.